In patients with poorly controlled Type 2 diabetes, biphasic insulin aspart 30 combined with metformin provides better glycaemic control than sulphonylurea/metformin combination

Abstrakt

In patients with Type 2 diabetes with good-to-moderate and poor glycaemic control, the efficiacy of BIAsp 30 in combination with metformin (MB) was compared to BIAsp 30 monotherapy (B)and to sulfonylurea in combination with metformin (MS).